Evidence map›Paper›PMID 41552399›Full record

ArticleUrology case reports2026

Early-onset fatal toxic epidermal necrolysis after first-cycle enfortumab vedotin in an elderly patient with metastatic urothelial carcinoma.

Fumihiro Ito, Koki Kobayashi, Yurika Sawasaki, Gaku Hayashi, Shunsuke Kamijo, Akitaka Shibata, Takashi Fujita

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fumihiro ItoDepartment of Urology, Gifu Prefectural Tajimi Hospital, 5-161 Maehata-cho, Tajimi, Gifu, 507-8522, Japan.
Koki KobayashiDepartment of Urology, Gifu Prefectural Tajimi Hospital, 5-161 Maehata-cho, Tajimi, Gifu, 507-8522, Japan.
Yurika SawasakiDepartment of Dermatology, Gifu Prefectural Tajimi Hospital, 5-161 Maehata-cho, Tajimi, Gifu, 507-8522, Japan.
Gaku HayashiDepartment of Urology, Gifu Prefectural Tajimi Hospital, 5-161 Maehata-cho, Tajimi, Gifu, 507-8522, Japan.
Shunsuke KamijoDepartment of Urology, Gifu Prefectural Tajimi Hospital, 5-161 Maehata-cho, Tajimi, Gifu, 507-8522, Japan.
Akitaka ShibataDepartment of Dermatology, Gifu Prefectural Tajimi Hospital, 5-161 Maehata-cho, Tajimi, Gifu, 507-8522, Japan.
Takashi FujitaDepartment of Urology, Gifu Prefectural Tajimi Hospital, 5-161 Maehata-cho, Tajimi, Gifu, 507-8522, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 86-year-old man with metastatic urothelial carcinoma developed fever, mucosal erosions, and rapidly progressive widespread erythema shortly after completing the first cycle of enfortumab vedotin (EV). Skin biopsy showed full-thickness epidermal necrosis consistent with toxic epidermal necrolysis (TEN). EV was discontinued and high-dose corticosteroids, intravenous immunoglobulin, and intensive supportive care were administered; however, the patient deteriorated rapidly and died of septic shock. This case demonstrates that EV-induced TEN may occur early and progress fulminantly, underscoring the need for prompt recognition and early dermatologic consultation.

Indexed as

Antibody–drug conjugateAntibody–drug conjugate toxicityDermatologic toxicityEnfortumab vedotinMetastatic urothelial carcinomaToxic epidermal necrolysis

Identifiers

PMID41552399
PMCPMC12811469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.